Key Highlights
- Eric Luthi appointed as Chief Business Officer at Koneksa.
- 25+ years of experience in life sciences, leading business development.
- Focus on digital biomarkers to drive clinical trial efficiency.
- Previous roles include Chief Commercial Officer at Evergreen Therapeutics.
- Proven record in commercial strategy and R&D integration.
Source: Business Wire
Notable Quotes
- “We’re thrilled to welcome Eric to lead our business development team. With his extensive industry expertise and proven success in driving growth and strategy, Eric will play a pivotal role in advancing our strategic initiatives and forming essential partnerships with leading healthcare organizations.” — Chris Benko, CEO and Co-Founder at Koneksa
- “I’m honored to join Koneksa as we continue to advance the role of evidence-based digital biomarkers in clinical trials to accelerate decision making and improve patient outcomes.” — Eric Luthi, Chief Business Officer at Koneksa
SoHC's Take
The appointment of Eric Luthi as Chief Business Officer represents a strategic move by Koneksa, underscoring its commitment to pioneering digital biomarkers that enhance clinical trials and expedite therapeutic developments. Luthi’s robust background in life sciences, particularly his success in integrating research and commercial strategies at both large and emerging companies, aligns well with Koneksa’s mission to leverage digital biomarkers for better data-driven insights in healthcare. His experience in building partnerships and driving revenue growth will likely accelerate Koneksa’s initiatives across diverse therapeutic areas, positioning the company as a leader in biomarker-driven clinical trial innovation.
